Coya Therapeutics (COYA) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Coya Therapeutics (COYA) over the past year, losing 30.8% versus a loss of 50.7%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $69.2 million), about 1.0 times the size, while Coya Therapeutics is growing revenue faster (+123.6% vs -34.8%). Zhengye Biotechnology converts more of its revenue into profit, with a net margin of -60.0% versus -267.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | ZYBT |
|---|---|---|
| Share price | $2.95 | $1.48 |
| Market cap | $69.20M | $70.14M |
| 1-day change | -1.01% | -2.63% |
| YTD return | -49.14% | +28.70% |
| 1-year return | -50.67% | -30.84% |
| EPS (TTM) | $-1.39 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | $16.64M |
| Revenue growth (YoY) | +123.57% | -34.83% |
| Net income (latest FY) | $-21.23M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | -283.87% | -60.60% |
| Net margin | -267.14% | -59.99% |
| 52-week high | $6.62 | $8.01 |
| 52-week low | $2.72 | $0.616 |
| Distance from 52-week high | -55.44% | -81.52% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +415.59% | — |
| Average volume | 149.18K | 569.22K |
| Shares outstanding | 23.46M | 47.39M |
| Employees | 8 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed COYA by 19.8 percentage points over the past year.
- Zhengye Biotechnology is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -267.1 cents for Coya Therapeutics.
- Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs -34.83%).
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
COYA vs ZYBT FAQ
Which is bigger, Coya Therapeutics or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $69.20M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or ZYBT?
ZYBT returned -30.84% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.